PMID- 28721137
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220330
IS  - 1734-1922 (Print)
IS  - 1896-9151 (Electronic)
IS  - 1734-1922 (Linking)
VI  - 13
IP  - 4
DP  - 2017 Jun
TI  - Beneficial effects of n-3 polyunsaturated fatty acids on adiponectin levels and 
      AdipoR gene expression in patients with type 2 diabetes mellitus: a randomized, 
      placebo-controlled, double-blind clinical trial.
PG  - 716-724
LID - 10.5114/aoms.2016.62139 [doi]
AB  - INTRODUCTION: There is evidence that n-3 polyunsaturated fatty acids (n-3 PUFAs) 
      exert beneficial effects to improve type 2 diabetes mellitus (T2DM), but its 
      complications remain poorly understood. Hypoadiponectinemia is one of the 
      important mechanisms responsible for T2DM which necessitates developing novel 
      therapeutic strategies. We aimed to determine the effect of n-3 PUFA 
      supplementation on circulating adiponectin and mRNA expression of adiponectin 
      receptors (AdipoR1, AdipoR2) and Sirt-1 in T2DM patients. MATERIAL AND METHODS: A 
      randomized, double-blind, placebo-controlled trial of 10-week follow-up of n-3 
      PUFAs (2.7 g/day) vs. placebo in T2DM patients (n = 88) was conducted. In detail, 
      T2DM patients (n = 44) were treated with n-3 PUFAs and the remainder received 
      placebo. Anthropometric and metabolic characteristics were assessed in all 
      participants. Circulating level of adiponectin and mRNA expression of AdipoR1, 
      AdipoR2 and Sirt-1 were measured in peripheral blood mononuclear cells (PBMC) 
      using real-time polymerase chain reaction before and after the intervention. 
      RESULTS: It was found that n-3 PUFAs increased AdipoR1 gene expression (fold 
      change = 1.321 in n-3 PUFAs vs. 1.037 in placebo) and AdipoR2 mRNA (fold change = 
      1.338 in n-3 PUFAs vs. 1.034 in placebo). No significant changes were observed 
      for Sirt-1 expression. The serum level of adiponectin significantly (p = 0.035) 
      increased in n-3 PUFAs (5.09 to 5.58 mug/ml) but remained unchanged in the placebo 
      group. CONCLUSIONS: Daily supplementation with n-3 PUFAs (2.7 g) was effective to 
      significantly improve gene expression of AdipoR1 and AdipoR2 and the serum level 
      of adiponectin in T2DM patients. Therefore, n-3 PUFAs might emerge as an adjuvant 
      for current antidiabetic therapies. However, confirmatory long-term studies are 
      required.
FAU - Mazaherioun, Maryam
AU  - Mazaherioun M
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, International Campus, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Saedisomeolia, Ahmad
AU  - Saedisomeolia A
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, International Campus, Tehran University of Medical Sciences, 
      Tehran, Iran.
AD  - Discipline of Nutrition and Metabolism, School of Molecular Bioscience, 
      University of Sydney, NSW, Sydney, Australia.
FAU - Javanbakht, Mohammad Hassan
AU  - Javanbakht MH
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, International Campus, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Koohdani, Fariba
AU  - Koohdani F
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, International Campus, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Eshraghian, Mohammad Reza
AU  - Eshraghian MR
AD  - Department of Biostatistics, School of Public Health, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Djalali, Mahmoud
AU  - Djalali M
AD  - Department of Cellular and Molecular Nutrition, School of Nutritional Sciences 
      and Dietetics, International Campus, Tehran University of Medical Sciences, 
      Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20160902
PL  - Poland
TA  - Arch Med Sci
JT  - Archives of medical science : AMS
JID - 101258257
PMC - PMC5507109
OTO - NOTNLM
OT  - Sirt-1
OT  - adiponectin
OT  - adiponectin receptors
OT  - n-3 poly-unsaturated fatty acids
OT  - peripheral blood mononuclear cells
OT  - randomized controlled trial
OT  - type 2 diabetes mellitus
COIS- The authors declare no conflict of interest.
EDAT- 2017/07/20 06:00
MHDA- 2017/07/20 06:01
PMCR- 2017/06/01
CRDT- 2017/07/20 06:00
PHST- 2016/03/23 00:00 [received]
PHST- 2016/06/27 00:00 [accepted]
PHST- 2017/07/20 06:00 [entrez]
PHST- 2017/07/20 06:00 [pubmed]
PHST- 2017/07/20 06:01 [medline]
PHST- 2017/06/01 00:00 [pmc-release]
AID - 28291 [pii]
AID - 10.5114/aoms.2016.62139 [doi]
PST - ppublish
SO  - Arch Med Sci. 2017 Jun;13(4):716-724. doi: 10.5114/aoms.2016.62139. Epub 2016 Sep 
      2.